About Barrier Therapeutics
Barrier Therapeutics is a company based in Princeton (United States) founded in 2002 was acquired by Stiefel in June 2008. Barrier Therapeutics has raised $78 million across 2 funding rounds from investors including J P Morgan, Kbc and Stiefel. Barrier Therapeutics operates in a competitive market with competitors including Revance Therapeutics, Hugel, Dermavant, Sol-Gel Technologies and SkinMedica, among others.
- Headquarter Princeton, United States
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Barrier Therapeutics Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$78 M (USD)
in 2 rounds
-
Latest Funding Round
$32 M (USD), Series C
Oct 27, 2003
-
Investors
J P Morgan
& 5 more
-
Employee Count
Not available
-
Acquired by
Stiefel
(Jun 23, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Barrier Therapeutics
Barrier Therapeutics has successfully raised a total of $78M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $32 million completed in October 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Barrier Therapeutics
Barrier Therapeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include J P Morgan, Kbc and Stiefel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm backed by Johnson & Johnson
|
Locked | Locked | Locked | |
|
Early-stage companies are invested in globally by TL Ventures.
|
Locked | Locked | Locked | |
|
Invests in biotech firms developing life-saving drugs and technologies.
|
Locked | Locked | Locked |
Investor details for Barrier Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Barrier Therapeutics
Investment portfolio details for Barrier Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Barrier Therapeutics
Detailed financials for Barrier Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Barrier Therapeutics Comparisons
Peer comparison for Barrier Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Barrier Therapeutics
Barrier Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Revance Therapeutics, Hugel, Dermavant, Sol-Gel Technologies and SkinMedica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurotoxin products for aesthetic and therapeutic skin treatments are developed.
|
|
| Locked | Locked | Locked |
Therapeutics in aesthetics are developed, including botulinum toxin products.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory skin diseases are developed.
|
|
| Locked | Locked | Locked |
Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.
|
|
| Locked | Locked | Locked |
Skin care products are developed and manufactured by SkinMedica.
|
|
| Locked | Locked | Locked |
Plant-derived collagen is developed for tissue repair and 3D bioprinting.
|
Detailed competitors of Barrier Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Barrier Therapeutics
Complete news archive for Barrier Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Barrier Therapeutics
Barrier Therapeutics was founded in 2002.
Barrier Therapeutics is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Barrier Therapeutics is a funded company, having raised a total of $78M across 2 funding rounds to date.
Barrier Therapeutics was focussed on developing topical drugs for dermatology disorders. Its marketed products include Xolegel, a topical gel for seborrheic dermatitis; Vusion, an ointment for infants and children suffering from diaper dermatitis; and Solage, a solution for the solar lentigines. It was also developing Hyphanox for onychomycosis; Pramiconazole for onychomycosis, and skin and mucosal fungal infections; and Rambazole for psoriasis. In July 2008, it was acquired by Stiefel Laboratories for 148M.
Barrier Therapeutics's top competitors include Revance Therapeutics, Dermavant and Collplant.
Barrier Therapeutics has 6 investors. Key investors include J P Morgan, Kbc, Stiefel, Turmeric Acquisition Corp, and Johnson & Johnson Innovation – JJDC.